XBiotech Inc. XBIT
XBiotech Inc. (Nasdaq: XBIT) is an oncology drug developer. Its lead program, Natrunix (anti-IL-1 alpha antibody, formerly bermekimab), is in Phase 2 for pancreatic cancer and other oncology/inflammatory indications.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Natrunix | pancreatic cancer (Phase 2 complete; FDA discussions ongoing) | antibody | Phase 2 |
| Natrunix | rheumatoid arthritis (Phase 2, 233 subjects, complete; data deemed uninterpretable owing to site irregularities) | antibody | Phase 2 |
| Hutrukin | stroke (Phase I complete; Phase II on hold) | antibody | Phase 1 |
| MRSA therapeutic | methicillin-resistant Staphylococcus aureus infection | antibody | Phase 1 |
| Shingles, influenza and C. difficile programs | infectious disease | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.